原发性硬化性胆管炎患者肝胆恶性肿瘤发病率:系统综述与Meta分析
该系统综述与Meta分析检索Pubmed和Embase至2024年4月10日,纳入51项队列研究共26482例原发性硬化性胆管炎患者,总随访221258.1人年,采用随机效应模型合并发病率。结果显示胆管癌粗发病率为每1000人年9.31,肝细胞癌为1.73,胆囊癌为1.06;合并炎症性肠病者肝细胞癌风险可能更高。
要点
- 原发性硬化性胆管炎患者胆管癌发病率较高(每1000人年9.31),肝细胞癌和胆囊癌少见。
- 合并炎症性肠病的原发性硬化性胆管炎患者肝细胞癌发病率可能更高。
- 胆管癌发病率在样本量<200例的研究中更高,肝细胞癌发病率存在地区差异。
核心结论
- 原发性硬化性胆管炎患者胆管癌发病率较高,而肝细胞癌和胆囊癌少见。
- 合并炎症性肠病的原发性硬化性胆管炎患者肝细胞癌风险可能更高。
- 这些数据应在大样本前瞻性研究中验证,并可能指导循证监测策略的制定。
研究设计与样本
- 系统综述与Meta分析,检索Pubmed和Embase数据库自建库至2024年4月10日的队列研究。
- 纳入51项报告原发性硬化性胆管炎患者胆管癌、肝细胞癌或胆囊癌发病率的队列研究,共26482例患者,总随访221258.1人年。
主要发现
- 总体原发性硬化性胆管炎患者胆管癌、肝细胞癌、胆囊癌的合并发病率分别为每1000人年9.31(95%CI 6.84-12.67;I²=74%)、1.73(95%CI 1.20-2.51;I²=55%)、1.06(95%CI 0.85-1.31;I²=0%)。
- 合并炎症性肠病的原发性硬化性胆管炎患者胆管癌、肝细胞癌、胆囊癌的合并发病率分别为每1000人年7.16(95%CI 4.48-11.44;I²=96%)、2.19(95%CI 1.48-3.25;I²=58%)、1.52(95%CI 1.21-1.90;I²=0%)。
- 亚组分析显示,样本量<200例的研究中胆管癌发病率更高;肝细胞癌发病率存在显著地区差异(P=0.03),大洋洲最高,欧洲最低。
- Meta回归确定原发性硬化性胆管炎合并炎症性肠病与肝细胞癌发病率相关。
临床怎么用
- 原文结论指出这些数据应在大样本前瞻性研究中验证,并可能指导原发性硬化性胆管炎患者肝胆恶性肿瘤循证监测策略的制定。
局限性
- 胆管癌合并发病率存在显著异质性(I²=74%)。
- 合并炎症性肠病患者中胆管癌合并发病率存在显著异质性(I²=96%)。
- 肝细胞癌合并发病率存在中度异质性(I²=55%);合并炎症性肠病患者中为58%。
- 原文结论指出这些数据应在大样本前瞻性研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a known risk factor for hepatobiliary malignancies. We conducted a systematic review and meta-analysis of published studies to determine the incidence and risk factors for hepatobiliary malignancies in people with PSC. METHODS: Pubmed and Embase databases were searched from inception to April 10, 2024, for cohort studies reporting data on the incidence of cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC), or gallbladder cancer (GBC) in PSC. Pooled incidence rates with 95% confidence intervals (CIs) were estimated using a random effects model. RESULTS: We identified 51 eligible studies involving 26,482 patients. The total follow-up was 221,258.1 person-years (PYs). The pooled incidence rates for overall PSC were 9.31 (95% CI, 6.84-12.67; I2 = 74%), 1.73 (95% CI, 1.20-2.51; I2 = 55%), and 1.06 (95% CI, 0.85-1.31; I2 = 0%) per 1000 PYs for CCA, HCC, and GBC, respectively. In patients with PSC with inflammatory bowel disease (IBD), rates were 7.16 (95% CI, 4.48-11.44; I2 = 96%), 2.19 (95% CI, 1.48-3.25; I2 = 58%), and 1.52 (95% CI, 1.21-1.90; I2 = 0%) per 1000 PYs, respectively. Subgroup analysis showed that the incidence of CCA was higher in smaller studies (<200 patients), and the incidence of HCC varied significantly by region (P = .03), with Oceania having the highest incidence and Europe having the lowest. Meta-regression determined that PSC-IBD was associated with HCC incidence. CONCLUSION: The incidence of CCA in PSC is substantial, whereas HCC and GBC are rare. Patients with PSC-IBD may be at higher risk for HCC. These data should be validated in large, prospective studies, and may guide the development of evidence-based surveillance strategies for hepatobiliary malignancies in PSC.
引用
- Souza M, Lima LCV, Al-Sharif L, et al. Incidence of Hepatobiliary Malignancies in Primary Sclerosing Cholangitis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2024. PMID: 39709139. doi:10.1016/j.cgh.2024.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。